Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44395   clinical trials with a EudraCT protocol, of which   7407   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,395 result(s) found. Displaying page 1,701 of 2,220.
    «« First « Previous 1697  1698  1699  1700  1701  1702  1703  1704  1705  Next» Last»»
    EudraCT Number: 2020-005492-12 Sponsor Protocol Number: BDTX-189-01 Start Date*: 2021-05-27
    Sponsor Name:Black Diamond Therapeutics, Inc.
    Full Title: MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutation...
    Medical condition: NSCLC, breast cancer, biliary tract cancer, or cervical cancer, any other solid tumors with specific gene mutations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) NL (Prematurely Ended) ES (Completed) IT (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-000877-10 Sponsor Protocol Number: MWTBTXA Start Date*: 2021-07-14
    Sponsor Name:Bispebjerg Hospital, Department of Dermatology
    Full Title: Longevity of microwave thermolysis and botulinum toxin A for treatment of axillary hyperhidrosis: a randomized intra-individual trial
    Medical condition: Axillary hyperhidrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10020642 Hyperhidrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001972-12 Sponsor Protocol Number: AA1817 Start Date*: 2019-09-13
    Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital
    Full Title: A phase 1b/2 open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors and advanced breast cancer
    Medical condition: in phase 1b part: advanced and/or treatment refractory solid malignancies in phase 2 part : advanced or metastatic HER2-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070308 Refractory cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-004927-34 Sponsor Protocol Number: KET01-02 Start Date*: 2022-03-28
    Sponsor Name:Ketabon GmbH
    Full Title: A multicentre, double-blind, randomised, placebo-controlled phase II trial with a 3 week treatment period to assess the efficacy, safety and tolerability of add-on treatment with Ketamine hydrochlo...
    Medical condition: Treatment-resistant depression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001857-22 Sponsor Protocol Number: Methadone-010922 Start Date*: 2022-09-06
    Sponsor Name:Sygehus Sønderjylland, Orthopedic department
    Full Title: Perioperative Methadone for ameliorating postoperative pain and reduction in postoperative opioid consumption in hip fracture patients – Dosage adjusting pilot-study
    Medical condition: Hip fractures
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10068399 Trochanteric femoral fracture LLT
    25.0 100000004863 10086938 Pertrochanteric femoral fracture LLT
    25.0 100000004863 10086939 Intertrochanteric femoral fracture LLT
    20.1 100000004863 10017284 Fractured femoral neck LLT
    20.1 100000004863 10053653 Femur fracture subtrochanteric LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001103-17 Sponsor Protocol Number: INSTI01 Start Date*: 2021-01-11
    Sponsor Name:Cliniques universitaires Saint-Luc
    Full Title: Gut microbiota, pharmacogenetics and Integrase Strand Transfer Inhibitors response
    Medical condition: HIV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-005053-20 Sponsor Protocol Number: ML39235 Start Date*: 2018-02-06
    Sponsor Name:Polish Myeloma Consortium
    Full Title: A multicenter, single-arm, phase II study to evaluate a safety and efficacy of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed/refractory Waldenström Macroglobul...
    Medical condition: Waldenström's macroglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004851 10047802 Waldenstrom's macroglobulinaemias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004187-35 Sponsor Protocol Number: FACE-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Falun Hospital
    Full Title: The FACE (Facial nerve palsy And Cortisone Evaluation) study in children: a randomised double-blind, placebo-controlled, multicenter trial.
    Medical condition: Facial Nerve Palsy (Bells Palsy)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004852 10077335 Facial nerve paresis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-001064-26 Sponsor Protocol Number: TMC278LAHTX4002 Start Date*: 2024-05-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 4, Open-Label, Rollover Study to Provide Continued Access to Cabotegravir Long-acting Injection and Rilpivirine Long-acting Injection to Participants Living with Human Immunodeficiency Viru...
    Medical condition: Human Immunodeficiency Virus 1
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-003711-60 Sponsor Protocol Number: ALXN1840-WD-205 Start Date*: 2021-01-15
    Sponsor Name:Alexion Pharmaceuticals, Inc
    Full Title: A Phase 2, single-arm, pathologist-blinded study using liver biopsy specimens to assess copper concentration and histopathologic changes in patients with Wilson disease who are treated with ALXN184...
    Medical condition: Wilson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10047988 Wilson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003221-22 Sponsor Protocol Number: TAK-555-3010 Start Date*: 2024-01-15
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting o...
    Medical condition: Constipation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-000899-33 Sponsor Protocol Number: rescue RTX Start Date*: 2011-08-09
    Sponsor Name:Department of Endocrinology, Sahlgrenska University Hospital
    Full Title: Rituximab (RTX) therapy in steroid resistant patients or patients relapsing after intravenous steroids with active TAO Rescue RTX
    Medical condition: Thyroid associated opthalmopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000075-39 Sponsor Protocol Number: C4671026 Start Date*: 2022-04-05
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITAL...
    Medical condition: SARS-CoV-2 Infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BG (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2022-001796-14 Sponsor Protocol Number: CYTB323G12101 Start Date*: 2023-03-20
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus (srSLE).
    Medical condition: Systemic Lupus Erythematosus Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001807-35 Sponsor Protocol Number: GETUG-AFU35UC-0160-1715 Start Date*: 2018-10-08
    Sponsor Name:UNICANCER
    Full Title: Phase II study of maintenance anti-PD-L1 treatment with atezolizumab after chemo-radiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing
    Medical condition: Patients older than ≥18 years, muscle-invasive bladder cancer unfit for radical cystectomy because of age, comorbidities, and/or patient’s refusal.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002717-35 Sponsor Protocol Number: P170920J Start Date*: 2018-12-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP)
    Full Title: Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE)
    Medical condition: Adults ≥ 18 years with middle or low locally advanced resectable rectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038038 Rectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-004238-20 Sponsor Protocol Number: CC21000 Start Date*: 2024-02-06
    Sponsor Name:Vejle Hospital
    Full Title: BONG: Breathlessness and alternatives to Opioid treatment in Non-malign Groups of severe lung disease
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10075530 Medical cannabis therapy PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002615-15 Sponsor Protocol Number: BGBIL006 Start Date*: 2016-12-14
    Sponsor Name:Helse Bergen HF, Haukeland universitetssjukehus
    Full Title: A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced no...
    Medical condition: Advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000708-40 Sponsor Protocol Number: UC-0110/1719 Start Date*: 2018-12-05
    Sponsor Name:UNICANCER
    Full Title: Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial.
    Medical condition: Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004004-30 Sponsor Protocol Number: 111-205 Start Date*: Information not available in EudraCT
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia
    Medical condition: achondroplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10000452 Achondroplasia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1697  1698  1699  1700  1701  1702  1703  1704  1705  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 29 18:28:45 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA